Download - t-PA 4 PE in ED
![Page 1: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/1.jpg)
t-PA 4 PE in EDt-PA 4 PE in EDAdrian SkinnerAdrian Skinner
ED registrarED registrarAuckland HospitalAuckland Hospital
28/11/0228/11/02
![Page 2: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/2.jpg)
IntroductionIntroduction
Case reportCase report
Recent literature reviewRecent literature review
Discussion of indications for thrombolysis Discussion of indications for thrombolysis in PEin PE
![Page 3: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/3.jpg)
Case Report Mr N.H.Case Report Mr N.H.
Presenting complaintPresenting complaint 14/09/0214/09/02
Increasing S.O.B. 3-4 daysIncreasing S.O.B. 3-4 days
Chest Pains Several daysChest Pains Several days
![Page 4: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/4.jpg)
Recent HistoryRecent History
24 August24 August Admission Rapid AFAdmission Rapid AF CXR : heart size upper limit of normalCXR : heart size upper limit of normal Rx. AmiodaroneRx. Amiodarone Appendicectomy : normal appendixAppendicectomy : normal appendix
9 September9 September Persistent coughPersistent cough GP CXR normalGP CXR normal
![Page 5: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/5.jpg)
Other Past HistoryOther Past History
HyperlipidaemiaHyperlipidaemia Rx. bezafibrateRx. bezafibrate NKDANKDA
![Page 6: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/6.jpg)
Family HistoryFamily History
Mother warfarinised in later lifeMother warfarinised in later life ? reason? reason
![Page 7: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/7.jpg)
Social HistorySocial History
Lives with wifeLives with wife
Retired commercial cleanerRetired commercial cleaner
Ex smoker (40 years ago)Ex smoker (40 years ago)
Ethanol : 1 flagon beer/fortnightEthanol : 1 flagon beer/fortnight
![Page 8: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/8.jpg)
ExaminationExamination
Temperature 34.2C (tympanic)Temperature 34.2C (tympanic)HR 140,HSDNMHR 140,HSDNMRR 55, TML, normal breath soundsRR 55, TML, normal breath soundsBP 104/60BP 104/60Central cyanosisCentral cyanosis
OO2 2 saturation 84%saturation 84%
Cool peripheriesCool peripheriesAbdomen normalAbdomen normalNo pedal oedema No pedal oedema
![Page 9: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/9.jpg)
ECGECG
![Page 10: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/10.jpg)
ABG (oxygen 15L/min)ABG (oxygen 15L/min)
pH 7.42pH 7.42
pOpO2 2 6.64 kPa6.64 kPa
pCOpCO2 2 3.033.03
HCOHCO33-- 14.4 14.4
BE -9.3BE -9.3Lactate 5.7Lactate 5.7
sOsO2 2 84.7%84.7%
pOpO2 2 (A-a) = 9.94 kPa(A-a) = 9.94 kPa
![Page 11: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/11.jpg)
FBC and coagulationFBC and coagulation
Hb 158Hb 158
WCC 10.9WCC 10.9
Platelets 643Platelets 643
INR 1.3INR 1.3
APTT 27APTT 27
![Page 12: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/12.jpg)
BiochemistryBiochemistry
Sodium 137Sodium 137
Potassium 4.1Potassium 4.1
Glucose 15.2Glucose 15.2
Creatinine 0.16Creatinine 0.16
Troponin-T 0.18Troponin-T 0.18
![Page 13: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/13.jpg)
CXRCXR
Lost at GLHLost at GLH
Looked OK to usLooked OK to us
DCCM staff ? Oligaemic left lung fieldDCCM staff ? Oligaemic left lung field
![Page 14: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/14.jpg)
ECHO – trans-thoracicECHO – trans-thoracic
![Page 15: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/15.jpg)
TreatmentTreatment
High flow oxygenHigh flow oxygen
IV fluid : 3 litres normal salineIV fluid : 3 litres normal saline
Enoxaparin 80mgEnoxaparin 80mg
ThrombolysisThrombolysis t-PA 100mg over 2 hours front loadedt-PA 100mg over 2 hours front loaded
![Page 16: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/16.jpg)
Clinical progressClinical progress
Rapid improvement towards completion of Rapid improvement towards completion of t-PA infusiont-PA infusion HR 110HR 110 RR 20-30RR 20-30 MAP 90MAP 90 OO2 2 saturation 100% on high-flow oxygensaturation 100% on high-flow oxygen
Transferred to DCCM via CT scannerTransferred to DCCM via CT scanner
![Page 17: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/17.jpg)
ECG post t-PAECG post t-PA
![Page 18: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/18.jpg)
CTPACTPA
![Page 19: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/19.jpg)
Further progressFurther progress
DCCM 1 dayDCCM 1 day
Transferred to GLH respiratory medicineTransferred to GLH respiratory medicine
Discharged day 7Discharged day 7
Repeat ECHO 1/10 RVSP 33mmHg + RAPRepeat ECHO 1/10 RVSP 33mmHg + RAP
Haematology review 25/10Haematology review 25/10 Improving effort toleranceImproving effort tolerance
Cardiology 4/11Cardiology 4/11 NSR 70/min normal effort toleranceNSR 70/min normal effort tolerance
GP remains wellGP remains well
![Page 20: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/20.jpg)
ECG 4/11/02ECG 4/11/02
![Page 21: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/21.jpg)
Acute Pulmonary EmbolismAcute Pulmonary Embolism
Clinical course and outcome dependent onClinical course and outcome dependent on 1) Extent of pulmonary arterial obstruction1) Extent of pulmonary arterial obstruction 2) Pre-existing cardiopulmonary disease2) Pre-existing cardiopulmonary disease 2) Potential for recurrent thrombo-embolic 2) Potential for recurrent thrombo-embolic
eventsevents
![Page 22: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/22.jpg)
MortalityMortality
All PE < 5%All PE < 5%
PE with RV dysfunction 10-15%PE with RV dysfunction 10-15%
PE with shock > 30%PE with shock > 30%
![Page 23: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/23.jpg)
Prognostic value of Prognostic value of Troponin-TTroponin-T
56 Patients with confirmed PE56 Patients with confirmed PE Graded as massive (n=17), moderate (n=26), small (n=13)Graded as massive (n=17), moderate (n=26), small (n=13)
Troponin positive (> 0.1ng/ml)Troponin positive (> 0.1ng/ml) 50%,50%,0%50%,50%,0%
In-hospital deaths (n=9)In-hospital deaths (n=9) SyncopeSyncope OR 7.1 (1.2-33.3)OR 7.1 (1.2-33.3) ShockShock OR 11.4 (2.1-63.4)OR 11.4 (2.1-63.4) Troponin +ve Troponin +ve OR 29.6 (CI 3.3-265.3)OR 29.6 (CI 3.3-265.3) InotropesInotropes OR 37.6 (5.8-245.6)OR 37.6 (5.8-245.6) VentilationVentilation OR 78.8 (9.5-653.2)OR 78.8 (9.5-653.2)
Giannitsis et al Circulation 2000;102:211-217Giannitsis et al Circulation 2000;102:211-217
![Page 24: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/24.jpg)
Giannitsis et alGiannitsis et al
![Page 25: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/25.jpg)
Thrombolysis for PEThrombolysis for PE
Early trials from 1970’sEarly trials from 1970’s
Small numbersSmall numbers
Multiple therapeutic regimensMultiple therapeutic regimens
Haemodynamically unstable patients Haemodynamically unstable patients excludedexcluded
Mortality in Haemodynamically stable Mortality in Haemodynamically stable patients @ 5-10%patients @ 5-10%
![Page 26: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/26.jpg)
First RCT in massive PEFirst RCT in massive PE
Streptokinase + Heparin ‘v’ Heparin onlyStreptokinase + Heparin ‘v’ Heparin onlyStudy stopped early after 8 enrolmentsStudy stopped early after 8 enrolments4 streptokinase patients alive and well4 streptokinase patients alive and well Clinical improvement within 1 hourClinical improvement within 1 hour
4 heparin-only all died4 heparin-only all diedTo date the only RCT in massive PETo date the only RCT in massive PE
Sanchez et al J Thromb Thrombolysis Sanchez et al J Thromb Thrombolysis 1995;2(3):227-2291995;2(3):227-229
![Page 27: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/27.jpg)
PE + RV dysfunctionPE + RV dysfunction
Grifoni et al Circulation 2000;101: 2817-2822Grifoni et al Circulation 2000;101: 2817-2822
![Page 28: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/28.jpg)
PE with right ventricle dilatationPE with right ventricle dilatation
128 patient monocentre registry 1992-1997128 patient monocentre registry 1992-1997
Massive PE and RV dysfunctionMassive PE and RV dysfunction No shock or hypotensionNo shock or hypotension
Thrombolysis ‘v’ heparinThrombolysis ‘v’ heparin
Significant improvement in perfusion scan at 7 Significant improvement in perfusion scan at 7 days with lysisdays with lysis
4 deaths in lysis group4 deaths in lysis group
None in heparin groupNone in heparin groupHamel et al CHEST 120; 1 July 2001 =: 120-125Hamel et al CHEST 120; 1 July 2001 =: 120-125
![Page 29: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/29.jpg)
Massive PE + pulmonary Massive PE + pulmonary hypertension or RV dysfunctionhypertension or RV dysfunction
RCT (n=256) alteplase + heparin ‘v’ RCT (n=256) alteplase + heparin ‘v’ heparinheparin
No hypotension or shockNo hypotension or shock
Deaths 3.4% v 2.2% p=0.71Deaths 3.4% v 2.2% p=0.71
Treatment escalationTreatment escalation 10.2% v 24.6% p=0.00610.2% v 24.6% p=0.006
Konstantinides et al NEJM 347, No.15;10 Oct 2002: Konstantinides et al NEJM 347, No.15;10 Oct 2002: 1143-11501143-1150
![Page 30: t-PA 4 PE in ED](https://reader036.vdocuments.net/reader036/viewer/2022062409/5681485d550346895db56b0a/html5/thumbnails/30.jpg)
ConclusionsConclusions
Patients with massive PE benefit from Patients with massive PE benefit from thrombolysisthrombolysis
Current research suggests that there may be a Current research suggests that there may be a subgroup of those with evidence of RV subgroup of those with evidence of RV dysfunction who will benefit from thrombolysisdysfunction who will benefit from thrombolysis
Further research required to determine this Further research required to determine this groupgroup
Trans thoracic ECHO is an important part of Trans thoracic ECHO is an important part of initial evaluationinitial evaluation